Catalyst Wire Dossier Catalyst Wire Dossier

Lentiviral vector gene therapy for X-linked chronic granulomatous disease

· University of California, Los Angeles
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lentiviral vector gene therapy for X-linked chronic granulomatous disease, covering 2025-05-02 to 2025-05-02. Get the full timeline:

Most recent: Clinical Trial Update: Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease [Phase 1, Phase 2]

See pricing